13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Recruiting now NCT05025878
Run by British Columbia Cancer Agency · for 18 and older · Women
What this study is about
The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \[U-13C\]glucose into patients during standard paracentesis.
Who can join (things the study team will check)
✅ You may be able to join if…
- Ovarian cancer
- Any stage or grade of disease
- Ascites fluid that requires draining
- Any treatment regimen
- Primary or recurrent ascites
- Understands the concept of the study and give informed consent.
🚫 You may not be able to join if…
- Participants must not have diabetes or abnormal hemoglobin A1C levels.
- The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada.
- Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.
Where this trial is running
- Jennifer Rauw, Victoria, British Columbia, Canada
Who to contact
Julian J. Lum, PhD · 250-519-5700 · JLum@bccancer.bc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05025878.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.